Table 4

Factors associated with reaching the treatment targets of MDA and cDAPSA LDA, in the total PsABio cohort and in the ustekinumab cohort and TNFi cohort

Test variable (baseline state)Total cohortUstekinumab cohortTNFi cohort
MDAcDAPSA LDAMDAcDAPSA LDAMDAcDAPSA LDA
No of patients, n*621614315306306308
Coefficient of determination, R20.320.320.360.360.350.35
 Line of bDMARD: first-line versus second-/third-line1.69
(1.13 to 2.53)
1.23
(0.84 to 1.78)
1.83
(1.02 to 3.29)
0.87
(0.50 to 1.50)
1.78
(0.99 to 3.22)
1.78
(1.02 to 3.09)
 Sex: female versus male0.50
(0.33 to 0.75)
0.60
(0.41 to 0.88)
0.34
(0.19 to 0.63)
0.40
(0.22 to 0.70)
0.58
(0.31 to 1.06)
0.80
(0.45 to 1.41)
 CV comorbidity/metabolic syndrome: present versus not present0.49
(0.32 to 0.76)
0.63
(0.42 to 0.93)
0.44
(0.23 to 0.83)
0.47
(0.26 to 0.84)
0.54
(0.30 to 1.00)
0.80
(0.46 to 1.41)
 Body mass index: per 1 kg/m20.97
(0.94 to 1.01)
0.97
(0.93 to 0.99)
0.97
(0.91 to 1.03)
0.99
(0.94 to 1.04)
0.98
(0.93 to 1.04)
0.94
(0.89 to 0.99)
 cDAPSA: per 10 score unit higher0.75
(0.64 to 0.88)
0.75
(0.66 to 0.85)
0.89
(0.73 to 1.08)
0.86
(0.72 to 1.02)
0.58
(0.44 to 0.76)
0.64
(0.52 to 0.79)
 PsAID-12 score: per one score unit higher0.86
(0.77 to 0.97)
0.87
(0.79 to 0.97)
0.84
(0.71 to 0.99)
0.82
(0.69 to 0.96)
0.88
(0.74 to 1.03)
0.92
(0.79 to 1.07)
 Enthesitis: present at baseline versus not present0.60
(0.40 to 0.92)
0.57
(0.38 to 0.84)
0.32
(0.17 to 0.62)
0.43
(0.24 to 0.78)
1.23
(0.66 to 2.27)
0.83
(0.47 to 1.49)
 Dactylitis: present at baseline versus not present1.05
(0.64 to 1.74)
1.16
(0.72 to 1.86)
0.56
(0.25 to 1.23)
0.64
(0.31 to 1.32)
2.15
(1.04 to 4.45)
2.01
(0.99 to 4.04)
 Psoriasis body surface area
 <3% vs 3%−10%0.89
(0.57 to 1.41)
1.66
(1.08 to 2.56)
1.17
(0.59 to 2.33)
2.08
(1.09 to 3.97)
0.61
(0.32 to 1.16)
1.33
(0.71 to 2.47)
 <3% vs >10%0.70
(0.40 to 1.24)
1.49
(0.88 to 2.52)
1.26
(0.57 to 2.78)
2.32
(1.11 to 4.84)
0.33
(0.13 to 0.86)
0.95
(0.42 to 2.17)
 NSAID treatment: yes versus no0.65
(0.42 to 1.01)
0.73
(0.49 to 1.09)
0.84
(0.40 to 1.74)
0.77
(0.41 to 1.45)
0.61
(0.34 to 1.12)
0.64
(0.37 to 1.11)
 Use of oral corticosteroids: yes versus no0.50
(0.27 to 0.92)
0.47
(0.27 to 0.80)
0.51
(0.21 to 1.25)
0.40
(0.16 to 0.86)
0.45
(0.19 to 1.08)
0.49
(0.23 to 1.03)
 FiRST score: per unit increase0.88
(0.78 to 0.98)
0.85
(0.77 to 0.95)
0.85
(0.72 to 1.00)
0.86
(0.74 to 1.00)
0.88
(0.74 to 1.05)
0.82
(0.70 to 0.96)
  • Data are OR (95% CI) unless otherwise stated.

  • *The n for the cohorts indicate the number of patients included in the respective model. Numbers are lower than total UST or TNFi patient cohorts due to missing variable data, such as missing patient-reported outcomes and skin assessments in some patients.

  • bDMARD, biological disease-modifying antirheumatic drug; cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; CV, cardiovascular; FiRST, Fibromyalgia Rapid Screening Tool; LDA, low disease activity; MDA, minimal disease activity; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsAID-12, 12-item Psoriatic Arthritis Impact of Disease questionnaire; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.